Research

Energy balance

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

LimitedQualifiesmedium confidence
However, high pricing (₹17,000–26,000/month) threatens equitable access.
Mehul Kaliya et al. · NMO journal · 2025

Why this rating

This is an opinion based on the abstract's discussion of pricing.

Source

Injectable Semaglutide (Wegovy) in India: Promise, Pitfalls and the Way Forward

Mehul Kaliya et al. · NMO journal · 2025

DOI 10.4103/jnmo.jnmo_55_25

reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →